NVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term strategy, and available capital, Novartis AG is not a strong buy at the moment. While the stock has positive long-term potential due to its pipeline assets and analyst upgrades, the current technical indicators and recent price trend suggest a neutral stance. Waiting for a more favorable entry point or additional positive catalysts may be prudent.
The MACD is positive but contracting, indicating weakening momentum. The RSI is neutral at 36.313, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its key support level (S1: 147.197), with a regular market change of -2.52%, suggesting short-term weakness.
Analysts have raised price targets significantly, reflecting confidence in pipeline assets like remibrutinib and del-brax. Novartis's RNA therapy del-brax has shown success in a Phase 1/2 trial for muscular dystrophy, indicating strong potential in the biotech space.
is up 0.78%, suggesting that Novartis's decline is stock-specific rather than market-driven.
No financial data available for analysis.
Morgan Stanley and BofA analysts have raised price targets to $170 and $178, respectively, and maintain Overweight/Buy ratings. Analysts are optimistic about the company's pipeline assets, particularly remibrutinib and del-brax.
